Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

BE1116

Phase 3Small molecule

1

Indications

3

Total Trials

1

Active Trials

0

Competitors

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Cardiopulmonary Bypass

NCT07094087

Clinical

Trials by Indication[1]

Cardiopulmonary Bypass1 trial

Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)

Recruiting· CSL Behring logo

CSL Behring·Phase 3·NCT07094087·200 enrolled

Injury1 trial

Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )

Terminated· CSL Behring logo

CSL Behring·Phase 3·NCT05568888·1,366 enrolled

Coagulopathy1 trial

Study of a Prothrombin Complex Concentrate for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Japanese Subjects

Completed· CSL Behring logo

CSL Behring·Phase 3·NCT02281201·11 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for BE1116. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BE1116 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BE1116. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSL Behring company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: CSL Behring

Related News